DNA

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Evolution of Ferment conference to kick off Summer 2025 BOSTON, Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is…

11 months ago

Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing…

11 months ago

DIGITAL celebrates continued investments in Canadian genomics

VANCOUVER, BC, Feb. 5, 2025 /CNW/ - DIGITAL, Canada's Global Innovation Cluster for digital technologies, is celebrating its ongoing impact…

11 months ago

UMC Utrecht adopts Volta Labs Callisto Sample Prep System to process thousands of samples for Whole Genome Sequencing-based prenatal and postnatal testing

BOSTON, Feb. 5, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and UMC Utrecht, one of the largest public…

11 months ago

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE…

11 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…

11 months ago

Legacy Education Inc. Schedules Second Quarter Fiscal Year 2025 Earnings Release and Conference Call

LANCASTER, Calif., Feb. 4, 2025 /PRNewswire/ -- Legacy Education Inc. ("Legacy Education" or the "Company") (NYSE American: LGCY) announces that…

11 months ago

Dubai Science Park unites talented leaders to explore future of longevity and wellness in the regional workplace and beyond

Region's leading science-focused ecosystem enables knowledge-sharing through inaugural thought-leadership forum by The DSP Leadership Network during Arab Health High-level platform…

11 months ago

Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approval On track to dose first patient…

11 months ago

Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approval On track to dose first patient…

11 months ago